Preprint Dabigatran etexilate and COVID-19
Thrombotic complications are frequent in COVID-19. There is evidence supporting the use of prophylactic dose low molecular weight heparin (LMWH) as prophylaxis for venous thromboembolism in critically ill patients. Indeed, all patients with COVID-19 that are admitted to hospital should receive prophylactic dose of LMWH. Dabigatran etexilate (Pradaxa) is an active direct thrombin inhibitor that inhibits clot-bound and circulating thrombin. Based on virtual screening results dabigatran etexilate is also a potential SARS-CoV-2 inhibitor. Therefore, dabigatran could be a new therapeutic option for the prophylaxis and treatment of COVID-19 associated thromboembolism, but further clinical research is mandatory.
What to you think?
Thank you all in advance!
Dear Domina Petric,
Respectfully I believe it unlikely. The dabigratan will have effects if the D- dimer is at high levels or if there is an evident thrombosis.
However, the effect of the heparin as an anti-inflammatory seen by the first 30 articles published last year on the indication of heparin in Sars Cov 2. ]
All of these publications reported, an anti-inflammatory effect and ultimately inhibited the formation of interleukin 6
As a recognized anti protease, standard heparin should be the first option, but we recognize the superiority of LWMH in administration and follow-up.
Best Regards
Carlos